CASI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CASI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. CASI Pharmaceuticals's Operating Income for the three months ended in Dec. 2024 was $-12.35 Mil. CASI Pharmaceuticals's Interest Expense for the three months ended in Dec. 2024 was $-0.16 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for CASI Pharmaceuticals's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for CASI Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CASI Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Interest Coverage | Get a 7-Day Free Trial |
![]() |
![]() |
N/A | N/A | - | - | - |
CASI Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Interest Coverage | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
N/A | - | - | - | - |
For the Biotechnology subindustry, CASI Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
CASI Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as
Here, for the fiscal year that ended in Dec. 2024, CASI Pharmaceuticals's Interest Expense was $-0.87 Mil. Its Operating Income was $-39.21 Mil. And its Long-Term Debt & Capital Lease Obligation was $2.54 Mil.
CASI Pharmaceuticals did not have earnings to cover the interest expense. |
CASI Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as
Here, for the three months ended in Dec. 2024, CASI Pharmaceuticals's Interest Expense was $-0.16 Mil. Its Operating Income was $-12.35 Mil. And its Long-Term Debt & Capital Lease Obligation was $2.54 Mil.
CASI Pharmaceuticals did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
CASI Pharmaceuticals (NAS:CASI) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of CASI Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
James Huang | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Wei-wu He | director, 10 percent owner, officer: Chairman and CEO | ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Weihao Xu | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Larry Zhang | officer: President | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Shrotriya Rajesh C Md | director | 157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Salisbury Franklin Cary Jr | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
Wealth Strategy Holding Ltd | 10 percent owner | LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK |
Alexander A Zukiwski | officer: Chief Medical Officer | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
George Chi | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Dapeng Li | 10 percent owner | BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008 |
Idg-accel China Growth Fund Iii L.p. | 10 percent owner | UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000 |
Spectrum Pharmaceuticals Inc | 10 percent owner | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Sparkle Byte Ltd | 10 percent owner | P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000 |
Ken Ren | director, officer: CEO and Director | 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065 |
From GuruFocus
By PRNewswire PRNewswire • 04-26-2023
By PRNewswire • 04-08-2024
By PRNewswire • 08-01-2023
By ACCESSWIRE • 11-15-2024
By PRNewswire • 06-26-2024
By GuruFocus News • 11-13-2024
By PRNewswire • 07-08-2024
By ACCESSWIRE • 01-06-2025
By PRNewswire PRNewswire • 12-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.